You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,181,552


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,181,552
Title:Materials and methods directed to asparagine synthetase and asparaginase therapies
Abstract: Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.
Inventor(s): Lorenzi; Philip L. (Washington, DC), Weinstein; John N. (Chevy Chase, MD), Caplen; Natasha J. (Silver Spring, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:13/151,420
Patent Claims:1. A kit comprising (a) at least one probe for detecting a level of expression of an endogenous asparagine synthetase (ASNS) gene protein product in a sample from a human subject and (h) at least one standard comprising at least one human cell expressing a level of an ASNS protein, wherein the level of expression in the sample is associated with an efficacy of L-asparaginase (L-ASP) in decreasing cell proliferation and the efficacy is identified based on comparison of the level of expression detected by the probe in the sample to the level of expression detected by the probe in the standard, wherein a higher level of expression in the sample compared to the standard indicates a lower efficacy of L-ASP in decreasing cell proliferation in the sample compared to the standard and wherein a lower level of expression in the sample compared to the standard indicates a higher efficacy of L-ASP in decreasing cell proliferation in the sample compared to the standard, wherein the probe is a non-human antibody or an antigen binding fragment thereof that specifically binds to an epitope of an ASNS protein.

2. The kit of claim 1, wherein the epitope comprises SEQ ID NO: 16.

3. The kit of claim 1, wherein the antibody or fragment thereof further comprises a detectable label.

4. The kit of claim 3, wherein the label is selected from the group consisting of a radiolabel, a fluorescent label, an epitope recognizable by a secondary antibody, and any combination thereof.

5. The kit of claim 1, wherein the kit further comprises a secondary antibody or antigen binding fragment thereof that specifically binds the probe antibody or antigen binding fragment thereof.

6. The kit of claim 1, wherein the antibody or antigen binding fragment thereof is humanized.

7. The kit of claim 1, wherein the kit further comprises an ASNS antagonist, wherein the ASNS antagonist is siRNA.

8. The kit of claim 7, wherein the siRNA targets a nucleotide sequence of SEQ ID NO 7, SEQ ID NO 8, or a full complement thereof.

9. The kit of claim 7, wherein the siRNA is siASNS.1 or siASNS.2.

10. A kit comprising (a) at least one probe for detecting a level of expression of an endogenous asparagine synthetase (ASNS) gene protein product in a sample from a human subject, (b) at least one standard comprising at least one human cell expressing a level of an ASNS protein, wherein the level of expression in the sample is associated with an efficacy of L-asparaginase (L-ASP) in decreasing cell proliferation and the efficacy is identified based on comparison of the level of expression detected by the probe in the sample to the level of expression detected by the probe in the standard, wherein a higher level of expression in the sample compared to the standard indicates a lower efficacy of L-ASP in decreasing cell proliferation in the sample compared to the standard and wherein a lower level of expression in the sample compared to the standard indicates a higher efficacy of L-ASP in decreasing cell proliferation in the sample compared to the standard, wherein the probe is a non-human antibody or an antigen binding fragment thereof that specifically binds to an epitope of an ASNS protein, and (c) at least one L-ASP.

11. The kit of claim 10, wherein the at least one L-ASP is pegylated.

12. The kit of claim 10, wherein the epitope comprises SEQ ID NO: 16.

13. The kit of claim 10, wherein the antibody or antigen binding fragment thereof is humanized.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.